DotBio

DotBio Focuses on Developing Novel Immuno-Oncology Drugs Based on Humanized Domain Antibodies, Its Proprietary DotBody Technology. DotBodies Are Domain Therapeutic Antibodies with Multi-Specificity, Humanization, and High Stability. The Company Was Founded by Professor Pär Nordlund and Dr. Ignacio Asial, Who Designed and Conceptualized the DotBody Technology Based on the Expertise in Protein and Antibody Engineering at Nanyang Technological University, Singapore.